Objective To observe the effect of alpha lipoic acid on quality of life in patients with type 2 diabetic peripheral neuropathy.Methods 76 cases diagnosed with type 2 diabetic peripheral neuropathy,in accordance with the random number table,were divided into the control group (37cases)and treatment group (39cases).All the patients received diabetic diet,exercise guidance and blood glucose control.The control group was treated with methy-cobal 500μg muscle injection once a day for 2 weeks.The treatment group was treated besides above treatment with intravenous drip alpha lipoic acid 600mg once a day was added for 2 weeks.Then,the changes of motor nerve conduc-tion velocity,sensory nerve conduction velocity and quality of life (QoL)score (somatic symptoms,cognitive func-tion,health happy feeling,social participation,emotional state,work performance,life satisfaction and total score)of the two groups after treatment were observed.Results After treatment,the motor nerve conduction velocity of the control group were as follows:median nerve (40.7 ±4.5)cm/s,common peroneal nerves (41.3 ±4.9)cm/s,The sensory nerve conduction velocity of the control group were as follows:median nerve (38.6 ±4.3)cm/s,common per-oneal nerves (38.3 ±4.5)cm/s.After treatment,the motor nerve conduction velocity of the treatment group were as follows:Median nerve (45.4 ±5.7)cm/s,common peroneal nerves (44.9 ±6.4)cm/s,The sensory nerve conduction velocity of the treatment group were as follows:Median nerve (45.0 ±2.0)cm/s,common peroneal nerves (43.6 ± 3.2)cm/s.Both the two groups′motor nerve conduction velocity and sensory nerve conduction velocity were significantly increased after treatment (P <0.05).Compared with control group,the motor nerve conduction velocity and sensory nerve conduction velocity in the treatment group were significantly improved after treatment,which had statistically significance,(t =2.63,2.51,2.85,2.79,all P <0.05).After treatment,the somatic symptoms,cognitive function,health happy feeling,job performance,social participation,emotional state,life satisfaction and the total score of control group were (52.4 ±9.6)points,(27.0 ±7.8)points,(35.7 ±10.3)points,(19.6 ±7.3)points,(17.4 ± 3.1)points,(16.5 ±3.9)points,(185.4 ±40.7)points,respectively.After treatment,the somatic symptoms,cogni-tive function,health happy feeling,job performance,social participation,emotional state,life satisfaction and total score of treatment group were (41.9 ±7.4)points,(24.1 ±8.6)points,(28.3 ±9.2)points,(14.5 ±5.5)points, (12.6 ±5.6)points,(11.9 ±4.7)points,(135.0 ±38.7)points,respectively.The quality of life score of the treat-ment group was obviously lower than the control group,which had statistically significance,(t =5.14,2.54,2.96, 2.87,2.69,3.05,6.25,all P <0.05).Conclusion Alpha lipoic acid can improve the nerve conduction function of patients with type 2 diabetes peripheral neuropathy,and improve the quality of life.

Objective To discuss the effect of butylphthalide soft capsules in the treatment of type 2 diabetic patients with mild cog-nitive impairment.Methods Ninety cases of diagnosed type 2 diabetic with mild cognitive impairment were randomly divided into two groups:the treatment group (n=45) and the control group (n=45) .Patients in both groups were treated with the traditional therapy, but those in the study treatment group were given butylphthalide soft capsules.MoCA and P300 were used as the effect judge standard after June.Results Compared with the control group, the MoCA score was increased in the treatment group(P<0.01), P300 latency was shorten and P300 amplitude was increased (P<0.05).Conclusion Butylphthalide capsules can improve cognitive function in patients with type 2 diabetes patients with mild cognitive impairment, and worthy of further clinical promotion and application.

Objective To observe influence of atorvastatin to high sensitive C-reactlve protein in the new on-set type 2 diabetes of normal blood lipid with macrovascular disease. Methods 96 cases with the new onset type 2 diabetes of normal blood lipid with macrovascu]ar disease were randomly divided into two groups,the treatment group contains 49 cases who were given atorvastatin 10rag for 12 weeks,the control group contains 47 cases who were given placebo for 12 weeks. Two groups were underwent the following test,fasting plasma glucose(FBG) ,post-OGTT 2 hour plasma glucose(PPG) ,glycosy-lated hemoglobin(HbAic) ,total triglyceride(TG) ,total cholesterol(TC) ,low density lipoprotein cholesterol(LDL-C) ,high sensitive C-reactive protein(hs-CRP). Results High sensitive C-reactive pro-tein(hs-CRP) in treatment group is significantly lower than control group[(2.13±1.38) mg/L and (4.04±3.14) mg/L,P < 0.05]. Conclusion Atorvastatin can significantly decease the level of high sensitive C-reactive protein (hs-CRP) to the new onset type 2 diabetes of normal blood lipid with macrovascular disease.